奥曲肽在小细胞肺癌合并低钠血症患者中的临床应用观察
|
摘要
目的观察奥曲肽在小细胞肺癌合并低钠血症患者中对低钠血症的治疗疗效和安全性。方法 60例小细胞肺癌合并低钠血症患者分为2组,奥曲肽组24例采用奥曲肽联合化疗、补钠支持治疗,对照组36例采用化疗、补钠支持治疗,观察低钠血症纠正时间、参加化疗率、生活质量改善情况以及毒副反应。结果奥曲肽组低钠血症纠正时间为(4.86±1.76)d,对照组为(14.43±3.68)d,差异有统计学意义(P<0.05)。奥曲肽组参加化疗率为100.0%,高于对照组的83.3%,差异有统计学意义(P<0.05)。2组生活质量改善情况比较差异有统计学意义(P<0.05)。2组毒副反应发生情况比较差异无统计学意义(P>0.05)。结论奥曲肽联合化疗、补钠支持治疗可迅速纠正小细胞肺癌合并低钠血症患者的低钠血症情况,改善患者生活质量,有利于化疗的尽早进行。
Objective To observe the efficacy and safety of octreotide in the treatment of patients with small cell lung cancer combined with hyponatremia. Methods Sixty patients with small cell lung combined with hyponatremia were divided into two groups,24 patients of the octreotide group received octreotide,chemotherapy and sodium treatment,and 36 patients of the control group received chemotherapy and sodium treatment,the corrected blood sodium time,the chemotherapy rate,quality of life and toxicities were evaluated. Results The corrected blood sodium time of the octreotide group was shorter than that of the control group[( 4. 86 ± 1. 76) days vs( 14. 43 ± 3. 68) days,P <0. 05]. The chemotherapy rate of the octreotide group was higher than that of the control group( 100. 0% vs 83. 3%,P < 0. 05). The quality of life of the octreotide group was better than that of the control group( P < 0. 05). There was no statistical difference in the toxicities between the two groups( P < 0. 05). Conclusion The octreotide,chemotherapy and sodium treatment could correct the blood sodium of patients with small cell lung cancer combined with hyponatremia,and improve the quality of life,and promote the smooth progress of chemotherapy.
Objective To observe the efficacy and safety of octreotide in the treatment of patients with small cell lung cancer combined with hyponatremia. Methods Sixty patients with small cell lung combined with hyponatremia were divided into two groups,24 patients of the octreotide group received octreotide,chemotherapy and sodium treatment,and 36 patients of the control group received chemotherapy and sodium treatment,the corrected blood sodium time,the chemotherapy rate,quality of life and toxicities were evaluated. Results The corrected blood sodium time of the octreotide group was shorter than that of the control group[( 4. 86 ± 1. 76) days vs( 14. 43 ± 3. 68) days,P <0. 05]. The chemotherapy rate of the octreotide group was higher than that of the control group( 100. 0% vs 83. 3%,P < 0. 05). The quality of life of the octreotide group was better than that of the control group( P < 0. 05). There was no statistical difference in the toxicities between the two groups( P < 0. 05). Conclusion The octreotide,chemotherapy and sodium treatment could correct the blood sodium of patients with small cell lung cancer combined with hyponatremia,and improve the quality of life,and promote the smooth progress of chemotherapy.
引文
[1]陈一天,徐益琛,陶累累,等.小细胞肺癌中MTA1蛋白的表达及其与化疗敏感性和预后的关系[J].临床肿瘤学,2014,19(2):102-106.
[2]扈艳婷,王旭,马克威,等.老年小细胞肺癌合并抗利尿激素分泌不当综合征19例[J].中国老年学杂志,2014,34(3):793-794.
[3]戴鹏.局限期小细胞肺癌合并抗利尿激素分泌不当综合征的临床观察[J].肿瘤研究与临床,2013,25(2):52-53.
[4]胡义德,钱桂生.小细胞肺癌综合治疗:实践指南[J].中华肺部疾病杂志:电子版,2011,4(5):356-359
[5]张琼,郭其深.小细胞肺癌合并低钠血症的诊断与治疗[J].世界肿瘤杂志,2008,7(1):71-72.
[6]赵晨光,宋世辉,张鹏.小细胞肺癌合并低钠血症的临床分析[J].天津医科大学学报,2011,17(2):222-223,242.
[7]文博,刘凯,陈晓平.心衰治疗中选择性精氨酸加压素V2受体拮抗剂托伐普坦临床应用及研究进展[J].河北医学,2015,21(4):694-697.
[8]Ectopic ADH Syndrome Therapeutic Research Group,Yamaguchi K,Shijubo N,et al.Clinical implication of the antidiuretic hormone(ADH)receptor antagonist mozavaptan hydrochloride in patients with ectopic ADH syndrome[J].Jpn J Clin Oncol,2011,41(1):148-152.
[9]杨洋,杨妙.精氨酸加压素受体拮抗剂的研究进展[J].天津药学,2012,24(6):39-42.
[10]丛雪晶,贾宁,白春梅.生长抑素类似物在神经内分泌肿瘤治疗中的作用[J].癌症进展,2011,9(5):488-494.
[11]刘平,魏子白,于俊岩,等.生长抑素治疗小细胞肺癌引起的顽固性低钠血症1例[J].临床肿瘤学杂志,2012,17(8):767-768.
[2]扈艳婷,王旭,马克威,等.老年小细胞肺癌合并抗利尿激素分泌不当综合征19例[J].中国老年学杂志,2014,34(3):793-794.
[3]戴鹏.局限期小细胞肺癌合并抗利尿激素分泌不当综合征的临床观察[J].肿瘤研究与临床,2013,25(2):52-53.
[4]胡义德,钱桂生.小细胞肺癌综合治疗:实践指南[J].中华肺部疾病杂志:电子版,2011,4(5):356-359
[5]张琼,郭其深.小细胞肺癌合并低钠血症的诊断与治疗[J].世界肿瘤杂志,2008,7(1):71-72.
[6]赵晨光,宋世辉,张鹏.小细胞肺癌合并低钠血症的临床分析[J].天津医科大学学报,2011,17(2):222-223,242.
[7]文博,刘凯,陈晓平.心衰治疗中选择性精氨酸加压素V2受体拮抗剂托伐普坦临床应用及研究进展[J].河北医学,2015,21(4):694-697.
[8]Ectopic ADH Syndrome Therapeutic Research Group,Yamaguchi K,Shijubo N,et al.Clinical implication of the antidiuretic hormone(ADH)receptor antagonist mozavaptan hydrochloride in patients with ectopic ADH syndrome[J].Jpn J Clin Oncol,2011,41(1):148-152.
[9]杨洋,杨妙.精氨酸加压素受体拮抗剂的研究进展[J].天津药学,2012,24(6):39-42.
[10]丛雪晶,贾宁,白春梅.生长抑素类似物在神经内分泌肿瘤治疗中的作用[J].癌症进展,2011,9(5):488-494.
[11]刘平,魏子白,于俊岩,等.生长抑素治疗小细胞肺癌引起的顽固性低钠血症1例[J].临床肿瘤学杂志,2012,17(8):767-768.